Table 1. Baseline characteristics of ADPKD patients in the discovery and validation cohort.
| Variable | Discovery cohort | Validation cohort | P value* |
|---|---|---|---|
| n | 338 | 163 | |
| Female sex, n (%) | 190 (56) | 87 (53) | 0.55 |
| Age, years | 46 (38–52) | 49 (44–55) | <0.001 |
| Height, m | 1.75 (1.68–1.84) | 1.77 (1.70–1.84) | 0.18 |
| BMI, kg/m2 | 26 (23–28) | 26 (24–29) | 0.60 |
| eGFR, ml/min per 1.73m2 | 62 (45–85) | 50 (41–58) | <0.001 |
| HtTKV, ml/m | 935 (575–1398) | 1142 (775–1778) | 0.001 |
| Urine ACR, mg/mmol | 2.8 (1.1–6.4) | 4.2 (2.3–9.6) | <0.001 |
| Gene type mutation, n | 287 | 158 | |
| PKD1, n (%) | 222 (77) | 116 (73) | 0.06 |
| PKD2, n (%) | 50 (18) | 39 (25) | |
| None, n (%) | 15 (5) | 3 (2) |
Data in median and interquartile ranges. ACR, albumin-to-creatinine ratio; ADPKD, autosomal dominant polycystic kidney disease; eGFR, estimated glomerular filtration rate; htTKV, height-adjusted total kidney volume.
*P values were calculated using a Mann-Whitney U test in case of non-normally distributed data, and a chi-square test in case of categorical data.